Alaunos Therapeutics News

Alaunos Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 15 17:25 ET

Alaunos Therapeutics | 10-K: Annual report

Apr 1 07:36 ET

Alaunos Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Groenewald Ferdinand

Feb 28 21:49 ET

Alaunos Therapeutics | 8-K: Current report

Feb 22 16:49 ET

Alaunos Therapeutics | 8-K: Current report

Feb 20 16:10 ET

Alaunos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Discovery Capital Management, LLC(1.66%),Robert K. Citrone(1.66%), etc.

Feb 14 12:49 ET

Alaunos Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-MSD Partners, L.P.(9.2%),MSD Credit Opportunity Master Fund, L.P.(9.2%), etc.

Feb 13 18:21 ET

Alaunos Therapeutics | 8-K: Current report

Feb 1 12:17 ET

Alaunos Therapeutics | 8-K: Current report

Jan 29 08:48 ET

Alaunos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hogue Dale Curtis Jr.

Jan 23 00:00 ET

Alaunos Therapeutics | 8-K: Current report

Jan 22 00:00 ET

Alaunos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hogue Dale Curtis Jr.

Jan 3 00:00 ET

Alaunos Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Hogue Dale Curtis Jr.

Jan 3 00:00 ET

Alaunos Therapeutics | 8-K: Current report

Jan 2 00:00 ET

Alaunos Therapeutics | 8-K: Current report

Dec 28, 2023 00:00 ET

Alaunos Therapeutics | 8-K: Current report

Dec 22, 2023 08:00 ET

Alaunos Therapeutics | 8-K: Current report

Nov 15, 2023 07:30 ET

Alaunos Therapeutics | 8-K: Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

Nov 14, 2023 07:40 ET

Alaunos Therapeutics: Q3 2023 Earnings Report

Nov 14, 2023 07:35 ET

Alaunos Therapeutics | 8-K: Current report

Sep 28, 2023 16:01 ET